Weight loss effectiveness reaches 15.1%. Pfizer Inc.'s weight loss drug "Xianweiyin" has been approved in China.

China has officially approved the GLP-1 treatment drug Aenoglutide Injection (trade name: Xianweiyin) under the American pharmaceutical giant Pfizer Inc. (PFE.US) for long-term weight management in overweight or obese adults. The drug was originally independently developed by the domestic biopharmaceutical company Sciwind Biosciences. In February 2026, Pfizer Inc. acquired the exclusive commercialization rights for the product in mainland China by paying a maximum of $495 million in collaboration fees. This approval marks a strategic step for Pfizer Inc. in the field of metabolic diseases in China. Aenoglutide, as a new generation cAMP-preferring GLP-1 receptor agonist, has shown excellent performance in previous clinical studies in China. According to data disclosed on the Sciwind Biosciences website, in trials involving obese or overweight Chinese subjects, the drug achieved a weight loss rate of 15.1% compared to placebo controls, with over 92% of patients achieving clinically significant weight loss. The product not only effectively controls weight but also obtained approval for the indication of type 2 diabetes in January 2026 from the National Medical Products Administration (NMPA). "This is undoubtedly a major breakthrough in the field of weight management," Sciwind Biosciences commented on its official website. Pfizer Inc. announced on Friday through the WeChat platform that this decision will further intensify the market competition that analysts expect to reach billions of dollars in value in the coming years. Xianweiyin, as an injectable drug belonging to the GLP-1 receptor agonist category, faces competition from similar drugs sold by pharmaceutical companies such as Novo Nordisk A/S Sponsored ADR Class B (NVO.US), Eli Lilly (LLY.US), and INNOVENT BIO in the local market. Jean-Christophe Pointeau, President of Pfizer Inc. China, stated in a related declaration that through the collaboration with Sciwind, Pfizer Inc. aims to use its strong commercialization network to accelerate the delivery of innovative weight loss solutions to Chinese patients. For Sciwind, this nearly $500 million transaction includes upfront, registration, and sales milestone payments, providing ample cash flow support during the crucial IPO push. However, Pfizer Inc. spokesperson did not immediately respond to questions regarding pricing and specific dates for the product's launch in China.